How Medical Representatives Increase Prescription Share in India

India has over 600,000 medical representatives competing for the attention of roughly 1.3 million doctors. That is nearly one MR for every two doctors in the country. In this environment, success is rarely about visiting more doctors. It is about visiting the right doctors, with the right message, at the right time — and having the tools to make that happen consistently, territory after territory, month after month.

01. The scale of the challenge — India's pharma battlefield

No other country in the world has a pharmaceutical field force quite like India's. With over 600,000 MRs active across the country, the competition for a doctor's attention — and ultimately their prescription pad — is intense in a way that is difficult to overstate.

A typical doctor in a busy urban clinic may receive visits from 5 to 10 different MRs in a single day. Every one of them is carrying a product they believe is better. Every one of them has a monthly target. And every one of them has roughly the same amount of time — often less than five minutes — to make their case.

In this environment, the MRs who win are not necessarily the ones who work the hardest. They are the ones who work the smartest — who know which doctors to prioritise, what to say when they get there, and how to use data to stay one step ahead of the competition.

02. How an Indian pharma territory actually works

Before understanding how MRs increase prescriptions, it helps to understand the operational reality they work within. Indian pharmaceutical companies have developed one of the most structured field force systems in the world — built around a concept called the Daily Call Average (DCA).

The territory is further divided into geographic sub-areas called Patches — typically 15 to 20 per territory, each containing 8 to 15 doctors within a 2 to 5 kilometre radius. An MR covers one Patch per day, minimising travel time and maximising face time with doctors. The structure of a Patch determines how efficiently an MR can work. But what happens within each Patch — which doctors to prioritise, what message to deliver, what the RCPA data shows — is where the real competitive battle is won or lost.

03. Quality vs. quantity — the relationship problem

Here is the uncomfortable truth that every field force manager in India knows: covering 150–200 doctors in a month means most doctors receive exactly one visit per month. That is not a relationship. That is a transaction.

One visit a month is enough to keep a brand name in circulation. It is not enough to build the kind of trust that changes prescription behaviour. And when you have 600,000 MRs all operating on the same DCA model, visiting the same doctors at the same frequency, the MR who simply "does the rounds" blends into the noise.

This is why the smartest pharma companies have moved away from treating all doctors equally. The answer is not fewer doctors — it is smarter prioritisation. Specifically:

• Gold-tier doctors (your top 50–60) get 2–3 visits per month — one in the first 15 days, and one or two more across the cycle. These are the doctors whose prescriptions drive the majority of your territory's revenue.
• Silver-tier doctors get one visit per month with a clear, focused message.
• Bronze-tier doctors are monitored via RCPA and moved up the priority list when the data shows they are writing competitor prescriptions that could be converted.

The tier names themselves — Gold, Silver, Bronze, or A, B, C, or any classification your company already uses — matter less than the discipline of applying them consistently and tracking visits against targets set for each tier.

The challenge is knowing which doctors belong in which category — and keeping that classification current as prescribing patterns shift. That requires data. Specifically, it requires RCPA data.

04. Building trust-based doctor relationships

Despite the operational pressures of the DCA system, relationships remain the foundation of prescription growth. Doctors are busy, often sceptical, and constantly approached. The MRs who cut through are the ones who are genuinely useful — who bring relevant clinical information, respect the doctor's time, and show up consistently with something worth hearing.

The data backs this up. 84% of doctors see a pharma representative at least once a week, and 14% see them daily. Access is not the problem. Value is. The MR who becomes a trusted source of clinical information — rather than just another brand promoter — earns something no competitor can easily take away: a doctor's default preference.

05. Clinical knowledge that actually moves prescriptions

A doctor's time is among the most constrained resources in Indian healthcare. When an MR walks in, they often have three to five minutes — sometimes less. The MRs who make that time count arrive prepared with clear, clinical, and relevant product knowledge: what the drug treats, which patients benefit most, why it is better than the alternatives, and what the safety profile looks like.

Research shows it typically takes 7 to 10 MR visits to meaningfully change a doctor's prescribing behaviour. That means every visit needs to build on the last — reinforcing the clinical message, updating the doctor on new evidence, and staying relevant to the cases they are actually seeing. The MR who comes in with the same pitch every month is wasting the visit. The MR who comes in with something new and useful is investing in a relationship.

06. The art of detailing — why digital changes everything

Detailing — the structured presentation of a product during a doctor visit — has always been the core of pharmaceutical field sales. Done well, a three-minute detail can shift a doctor's thinking in ways that no advertisement or brochure can. Done poorly, it is forgotten before the MR reaches the staircase.

Traditional detailing relied on printed visual aids and verbal pitches. Modern detailing is a different game. e-Detailing — digital, interactive product presentations delivered on a tablet — allows MRs to walk doctors through clinical evidence in a structured, memorable way, leave behind digital materials the doctor can revisit, and adapt the conversation in real time based on what the doctor responds to.

The market agrees: the global e-Detailing market is projected to grow from $830 million in 2022 to over $2.1 billion by 2030, driven by pharma companies recognising that digital engagement produces better outcomes than paper. Critically, a BCG survey found that 60% of doctors still prefer learning about new products through in-person visits — meaning e-Detailing is not a replacement for the MR, but a powerful tool in the MR's hands.

07. RCPA — turning prescription data into competitive advantage

In the Indian pharma context, RCPA (Retail Chemist Prescription Audit) is not just a tool — it is the intelligence layer that separates strategic selling from guesswork. By visiting 5 to 10 retail chemists per day and tracking which prescriptions are being dispensed, an MR builds a real-time picture of exactly what each doctor in their territory is prescribing — and for which brands.

This data answers the most important questions in field sales: Which of my A-category doctors is writing competitor prescriptions? Which C-category doctor has just started writing in my therapy area and needs to be moved up the priority list? Which brand is gaining share in my patch — and why?

Without RCPA, an MR is visiting doctors based on habit and intuition. With RCPA, every visit is backed by evidence. The doctor who is already loyal gets a retention message. The doctor who is writing competitor brands gets a targeted conversion pitch. The result is a field force that works smarter, not just harder.

08. Smart tour planning — covering more ground, more effectively

Given that an Indian MR is expected to make 10 to 12 doctor visits per day across a territory of 150 to 200 doctors, tour planning is not an administrative task — it is a performance lever. A poorly planned day means 6 or 7 visits instead of 12. Multiply that across a team of 20 MRs over a month, and thousands of calls are being left on the table.

Smart tour planning, built around the Patch system and the 15-Day Priority Rule, ensures that:

• A-category doctors are always visited in the first 15 days of the month — securing early prescription momentum
• Each day is structured around a geographic Patch — minimising travel, maximising face time
• Visit frequency matches doctor category — high-value doctors get more attention, low-priority ones are not over-served
• No important doctor relationship goes cold due to a missed monthly visit

09. Product availability — the silent prescription killer

An MR can do everything right — build the relationship, deliver a compelling detail, secure the prescription commitment — and still lose the sale. If the doctor's patient goes to the chemist and the product is not on the shelf, the prescription gets substituted. The competitor wins. And the doctor quietly stops writing your brand.

This is why the chemist and stockist visits built into the Indian MR's daily routine are not secondary tasks — they are as important as the doctor calls. Visiting 5 to 10 chemists per day through RCPA also serves a dual purpose: it collects prescription intelligence and ensures shelf presence. Maintaining 2 to 4 stockist relationships per territory keeps the supply chain tight. When a doctor knows their prescription will always be filled, they prescribe with confidence — and they keep prescribing.

10. Metrics, performance and the manager's view

For a field force manager overseeing 20 MRs across multiple territories, the challenge is clear: how do you know what is actually happening in the field? DCA compliance, A-category doctor coverage, RCPA collection rates, detailing quality — all of these directly affect prescription outcomes, but none of them are visible without the right systems in place.

The best pharma companies in India have moved beyond manual DCR (Daily Call Reports) and Excel-based tracking. They use real-time dashboards that connect field activity to commercial outcomes — allowing managers to coach in the moment, catch problems before they compound, and allocate resources to the territories and MRs that need attention most.

11. The future-ready medical representative

The Indian pharmaceutical market is changing faster than at any point in its history. Doctors have less time, more information, and higher expectations from the MRs they choose to see. Pharma companies are under margin pressure. Competition for shelf space, chemist relationships, and doctor mindshare has never been more intense.

In this environment, the MR who will thrive is not the one who works the longest hours or covers the most doctors. It is the one who combines genuine clinical knowledge with data-driven decision-making and the right digital tools — who knows which 60 doctors to prioritise this month, what the RCPA data says about each of them, and how to make every five-minute detail count.

The companies that invest in equipping their field teams with the right pharma SFA tools and these capabilities will see faster brand adoption, stronger prescription loyalty, and better returns from every rupee spent on field sales. Those that don't will find their MRs working harder and harder for diminishing returns in an increasingly competitive market.